Reports have said that Beijing is speaking out against the US court that recently ordered two Chinese manufacturers of Vitamin C to pay $162 million in damages for price-fixing. The US court is now accused of infringing on Beijing’s sovereignty. A spokesman for China’s Ministry of Commerce spoke out against the US court at a press conference, arguing that the ruling was “unfair and improper” and that the accused companies were simply complying with the Chinese government’s requirements. Last week a federal court in New York ordered that North China Pharmaceutical Group Corp and one of its affiliates to pay the fine after the defendants argued that the “price-fixing cartel” found to have existed by the jury was the result of Chinese government decisions. The fines were trebled by the judge.
Full Content: Global Post
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI